175:
235:
CYC140, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel’s strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit www.cyclacel.com.
234:
Cyclacel
Pharmaceuticals, Inc. is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program
238:
Sir David Lane, PhD, a recognized leader in the field of tumor suppressor biology, who discovered the p53 protein, founded the company in 1996. In 1999, Cyclacel
Pharmaceuticals was joined by David Glover, PhD, a recognized leader in the mechanism of mitosis or cell division, who discovered, among
256:
261:
271:
251:
266:
29:
239:
other cell cycle targets, the mitotic kinases, Polo and Aurora, enzymes that act in the mitosis phase of the cell cycle.
219:
105:
131:
135:
122:
140:
95:
118:
127:
151:
159:
226:, Scotland, developing cancer treatments. Cyclacel was founded in 1996 by David Lane, PhD.
39:
245:
215:
67:
57:
47:
167:
223:
53:
28:
200:
195:
185:
165:
147:
112:
101:
91:
73:
63:
45:
35:
8:
257:Pharmaceutical companies based in New Jersey
21:
27:
20:
7:
262:Pharmaceutical companies of Scotland
14:
272:Science and technology in Dundee
174:
173:
16:US/UK biopharmaceutical company
252:Companies listed on the Nasdaq
22:Cyclacel Pharmaceuticals, Inc.
1:
212:Cyclacel Pharmaceuticals Inc.
220:Berkeley Heights, New Jersey
106:Berkeley Heights, New Jersey
79:; 27 years ago
288:
267:Companies based in Dundee
26:
187:Number of employees
141:Mark Kirschbaum, MD
23:
178:US$ 19.1 million
96:David P. Lane, PhD
209:
208:
181:
156:
155:(formerly CYC065)
279:
230:Company overview
205:
202:
179:
177:
176:
154:
134:, finance &
87:
85:
80:
31:
24:
287:
286:
282:
281:
280:
278:
277:
276:
242:
241:
232:
199:
188:
170:
158:
139:
126:
115:
83:
81:
78:
50:
17:
12:
11:
5:
285:
283:
275:
274:
269:
264:
259:
254:
244:
243:
231:
228:
218:firm based in
207:
206:
197:
193:
192:
189:
186:
183:
182:
171:
166:
163:
162:
149:
145:
144:
119:Spiro Rombotis
116:
113:
110:
109:
103:
99:
98:
93:
89:
88:
75:
71:
70:
65:
61:
60:
51:
46:
43:
42:
37:
33:
32:
15:
13:
10:
9:
6:
4:
3:
2:
284:
273:
270:
268:
265:
263:
260:
258:
255:
253:
250:
249:
247:
240:
236:
229:
227:
225:
221:
217:
216:biotechnology
213:
204:
198:
194:
190:
184:
172:
169:
164:
161:
153:
150:
146:
142:
137:
133:
129:
128:Paul McBarron
124:
120:
117:
111:
107:
104:
100:
97:
94:
90:
76:
72:
69:
68:Biotechnology
66:
62:
59:
55:
52:
49:
44:
41:
38:
34:
30:
25:
19:
237:
233:
211:
210:
102:Headquarters
36:Company type
18:
152:Fadraciclib
246:Categories
168:Net income
114:Key people
191:17 (2022)
48:Traded as
201:cyclacel
148:Products
64:Industry
196:Website
92:Founder
82: (
74:Founded
56::
224:Dundee
180:(2021)
160:CYC140
108:, U.S.
54:Nasdaq
40:Public
214:is a
143:(CMO)
222:and
203:.com
84:1997
77:1997
58:CYCC
136:COO
132:EVP
123:CEO
248::
157:,
138:)
130:(
125:)
121:(
86:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
